Sorry Sav, no link. I will have a good slow read and post any pertinent point. But the guts of it was "resistance"'. So they think BIT is in a strong posotion, subject to some more trials being successful. I posted about that on this thread.
So still a potentially ver valuable HCV drug, but needs more data.
My thoughts, good enough for a big player to pony up some development funds.
